Department of Health and Social Care written question – answered on 2nd December 2021.

Alert me about debates like this

Photo of Jesse Norman Jesse Norman Conservative, Hereford and South Herefordshire

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of Odevixibat for treating processive familial intrahepatic cholestasis.

Photo of Edward Argar Edward Argar Minister of State (Department of Health and Social Care)

The Department has made no assessment. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based recommendations for the National Health Service on whether licenced medicines represent a clinically and cost-effective use of resources.

NICE is currently appraising odevixibat for the treatment of progressive familial intrahepatic cholestasis through its highly specialised technologies programme and expects to publish final guidance in January 2022.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.